Natera (NASDAQ:NTRA) Director Roelof Botha Sells 78,000 Shares

Natera, Inc. (NASDAQ:NTRA) Director Roelof Botha sold 78,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director owned 1,076,198 shares in the company, valued at $237,097,181.38. This represents a 6.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Natera Trading Down 0.4%

Shares of NTRA stock opened at $211.85 on Thursday. The company has a market capitalization of $30.34 billion, a P/E ratio of -129.97 and a beta of 1.56. The business’s 50 day moving average is $203.28 and its two-hundred day moving average is $215.94. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in NTRA. Integrated Wealth Concepts LLC lifted its position in Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares in the last quarter. NewEdge Advisors LLC lifted its position in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its position in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in Natera during the second quarter worth approximately $298,000. Finally, WINTON GROUP Ltd purchased a new position in Natera during the second quarter worth approximately $558,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on NTRA. Robert W. Baird set a $265.00 target price on Natera in a research report on Friday, May 8th. Piper Sandler restated an “overweight” rating and issued a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. Wolfe Research began coverage on Natera in a research report on Tuesday. They issued an “outperform” rating and a $260.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Finally, Morgan Stanley decreased their target price on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $256.81.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.